Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine
January 12, 2025 10:00 ET
|
Curevo Vaccine
Updated Phase 2 data one year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix
Curevo Vaccine to present at the 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025 11:30 ET
|
Curevo Vaccine
Curevo Vaccine will present at the 2025 JPM Healthcare Conference on Wednesday January 15th.
CEPI and Accumulus Synergy team up to enhance information equity and accelerate access to vaccines
December 10, 2024 06:00 ET
|
Accumulus Synergy
OSLO, Norway and BURLINGAME, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy’s innovative cloud-based data-sharing platform could accelerate access to vaccines and other health...
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
November 21, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been awarded a $3 million grant from the Gates...
Pacific Genetech Hercules Delivery System Recognized With “Vaccine Innovation Of The Year” By BioTech Breakthrough
November 19, 2024 08:01 ET
|
BioTech Breakthrough
FAYETTEVILLE, Ark., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Pacific Genetech today announced that Hercules is the recipient of the “Vaccine Innovation Of The Year” award in the fourth annual BioTech...
Global Veterinary Vaccine Adjuvants Market to Reach USD 674.2 Million by 2034, Driven by Rising Demand for Animal Health Solutions | FMI
November 18, 2024 11:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The global veterinary vaccine adjuvants market is experiencing strong growth, with sales estimated to reach USD 431.4 million in 2024 and projected to...
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
November 12, 2024 08:00 ET
|
Evaxion Biotech
New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results also showcase the successful design of a proprietary...
HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
November 07, 2024 08:00 ET
|
HilleVax, Inc.
$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in...
Sabin Sends More Marburg Vaccines for Rwanda’s Outbreak
October 31, 2024 14:22 ET
|
Sabin Vaccine Institute
Photo caption: Rwanda Minister of State for Health, Yvan Butera, was among those who received Sabin’s investigational vaccine in the open-label clinical trial. WASHINGTON, Oct. 31, 2024 (GLOBE...
Curevo Presents Positive Shingles Vaccine Outcomes Data
October 31, 2024 02:00 ET
|
Curevo Vaccine
Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine